Allos Looks To ENRICH Trial To Secure Excelar Approval
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s Oncologic Drugs Advisory Committee says product requires confirmatory data for approval in brain metastases related to breast cancer. Open-label study began in February.
You may also be interested in...
Allos Oncologic Efaproxiral “Approvable” Pending Phase III ENRICH Data
FDA followed the recommendations of its Oncology Drugs Advisory Committee in issuing an “approvable” letter. Efaproxiral approval is also conditional on FDA clearance of Allos’ manufacturing facility and forthcoming agency comments on pharmacology, toxicology and chemistry issues.
FDA Antihypertensive Draft Class Labeling To Be Reviewed By Cardio-Renal Committee
FDA’s proposal for relabeling of antihypertensive agents is based on prior recommendations by the committee that information on cardiovascular outcomes related to blood pressure lowering be included as class labeling.